Q-omics provides the consensus-scored MPDZ profile across patient tissues and cancer cell-line models. MPDZ expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MPDZ is differentially expressed in 15, with the highest sampling consensus in LUSC. Additionally, MPDZ RNA expression shows 20,159 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, LUSC, and PDAC as cancer lineages where MPDZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPDZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPDZ survival associations across molecular data types. MPDZ RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPDZ RNA expression–survival associations across cancer types. High MPDZ expression shows unfavorable associations in MESO, UVM and BLCA, but favorable associations in KIRC, BRCA and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for MPDZ RNA expression.
This table summarizes MPDZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MPDZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPDZ shows lower tumor expression in LUSC, KICH, COAD, BLCA, UCEC and LUAD. The LUSC box plot shows higher MPDZ RNA expression in normal versus tumor tissue (log2 FC = −1.866, t-test p < 0.001).
This table shows molecular features associated with MPDZ in patient tissues and cancer cell lines. In patient samples, MPDZ shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MPDZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
